NeurologyLive® Friday 5 — April 11, 2025

Author(s):

Key Takeaways

Cellular immunology insights are crucial for understanding multiple sclerosis progression and treatment response, as discussed by Amit Bar-Or, MD.
AI-driven behavioral analysis enhances preclinical Alzheimer's research, offering better modeling and assessment of disease progression.
GLP-1 analogs show promise as neuroprotective agents across various neurodegenerative disorders, highlighting their broad therapeutic potential.
Intensive blood pressure management post-intracerebral hemorrhage is debated for its clinical rationale and evidence base.
CGRP-targeting therapies are emerging as a potential first-line option for migraine prevention, supported by evolving evidence and payor support.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 11, 2025.

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Understanding the Cellular Drivers of MS Progression and Treatment Response: Amit Bar-Or, MD, FRCPC, FAAN, FANA

The Melissa and Paul Anderson President’s Distinguished Professor of Neurology, Perelman School of Medicine, University of Pennsylvania discussed evolving insights into the cellular immunology of multiple sclerosis. [WATCH TIME: 4 minutes]

2: Advancing Preclinical Alzheimer Research Through AI and Behavioral Analysis: Stephanie R. Miller, PhD

The staff scientist at Gladstone Institutes talked about leveraging AI-driven behavioral analysis to better model and assess Alzheimer disease progression in preclinical studies. [WATCH TIME: 2 minutes]

3: GLP-1 Analogs Showing Broad Neuroprotective Potential Across Neurological Disorders: Paul Edison, MBBS, PhD, FRCPI

The professor of neuroscience at the Imperial College London discussed the emerging role of GLP-1 analogs as neuroprotective agents with potential benefits in neurodegenerative conditions. [WATCH TIME: 4 minutes]

4: NeuroVoices: Chitra Venkatasubramanian, MBBS, MD, MSc, FNCS, on Debating Optimal Blood Pressure Targets After Intracerebral Hemorrhage

The clinical professor of stroke neurology at Stanford University discussed the clinical rationale and evidence supporting early, intensive blood pressure lowering in patients with intracerebral hemorrhage.

5: CGRP Therapies as Potential First-Line Migraine Preventive Treatment: Andrew Charles, MD

The director of the UCLA Goldberg Migraine Program discussed the advantages, evidence base, and evolving payor support for CGRP-targeting therapies as potentially a first-line option in migraine prevention. [WATCH TIME: 5 minutes]